These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22142663)

  • 1. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
    Gnant M
    Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant bisphosphonates: a new standard of care?
    Gnant M
    Curr Opin Oncol; 2012 Nov; 24(6):635-42. PubMed ID: 23042123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of bone-conserving therapy in patients with breast cancer.
    Brufsky AM
    Semin Oncol; 2010 Jun; 37 Suppl 1():S12-9. PubMed ID: 20682367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
    Coleman RE
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bisphosphonates in postmenopausal women with breast cancer.
    Gnant M
    Cancer Treat Rev; 2014 Apr; 40(3):476-84. PubMed ID: 23906846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R; Gnant M; Morgan G; Clezardin P
    J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 18. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault RL
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.
    Candelaria-Quintana D; Dayao ZR; Royce ME
    Breast Cancer Res Treat; 2012 Apr; 132(2):355-63. PubMed ID: 21987034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.